SPDR S&P Biotech ETF Soars While Uranium ETF Declines
On Thursday, the SPDR S&P Biotech ETF rose approximately 1.9%, outperforming other ETFs. Notable gains were seen in Oric Pharmaceuticals, which surged about 33.8%, and Replimune Group, which increased by approximately 9.6%.
In contrast, the Uranium ETF fell by about 2.1% during Thursday afternoon trading. F3 Uranium experienced the most significant drop, declining by around 14.8%, while Mega Uranium also fell, down about 6.5%.
VIDEO: Thursday’s ETF Movers: XBI, URA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
